Verrica Pharmaceuticals (VRCA) Stock: Buy, Sell, or Hold?
VRCA - Verrica Pharmaceuticals Inc. Common Stock
$3.83
0.20 (5.51%)
â˛
5d:
+1.32%
30d:
-17.1%
90d:
-23.71%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 13, 2026
20d
Get Alerted When VRCA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VRCA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VRCA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VRCA is currently trading at $3.83, which is considered slightly low relative to its 30-day fair value range of $3.81 to $4.63.
Technical Outlook: Technically, VRCA is in a strong downtrend. Immediate support is located at $3.30, while resistance sits at $4.38. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: VRCA scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.83 (+261.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRCA is in a strong downtrend. Immediate support is located at $3.30, while resistance sits at $4.38. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: VRCA scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $13.83 (+261.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.81 -
$4.63
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.5%)
- BULLISH: Trading 261.2% below Wall St target ($13.83)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.81 -
$4.63
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.30
Resistance Level
$4.38
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.09
Wall Street Target
$13.83
(+261.2%)
Revenue Growth (YoY)
-53.9%
Profit Margin
-102.8%
Share & Embed Analysis
Last updated: October 23, 2026 4:56 AM ET
Data refreshes hourly during market hours. Next update: 5:56 AM
Data refreshes hourly during market hours. Next update: 5:56 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRCA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 66 BUY |
|
CGON
CG Oncology, Inc. CommonâĻ |
STRONG BUY
15 analysts |
$91 | 64 BUY |
